Prospective observational investigation of possible correlations between change in FVC and change in cough or dyspnea scores using the living with pulmonary fibrosis questionnaire (L-PF) between baseline and after approximately 52 weeks of nintedanib treatment in patients suffering from chronic fibrosing ILD with a progressive phenotype. (INREAL)

24/11/2020
15/05/2025
EU PAS number:
EUPAS38272
Study
Finalised
Documents
Study protocol
Study results
Study report
Other information